Unaudited Financial Statement for the Quarter Ended 30th June 2025
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Amrutanjan Health Care posted strong Q1 FY26 results with revenue from operations rising about 12% year-on-year to ₹9,404.57 lakhs (from ₹8,373.60 lakhs in Q1 FY25). Profit after tax jumped roughly 80% to ₹831.12 lakhs (from ₹461.56 lakhs), and basic EPS climbed to ₹2.87 from ₹1.60. Profit before tax margin expanded sharply to about 12% from 7.6% a year ago, helped by lower purchase of traded goods and controlled advertising spends. On the segment side, OTC Products and Women's Hygiene swung to better results, while the Beverages segment continued to post a loss (though narrower than the previous year). The board also appointed SPNP & Associates as Secretarial Auditor for five years and set September 16, 2025 as the record date for the final dividend and AGM voting, with the 88th AGM scheduled for September 23, 2025.
Sharp PAT growth and margin expansion signal strong operating momentum and could be positive for the stock in the near term. The continued Beverages segment loss remains a watchpoint, but overall earnings quality looks improved for retail shareholders.